Noradrenalin (Norepinephrin) Aguettant (Noradrenaline Tartrate)

Noradrenaline acts as an alpha‑adrenergic receptor agonist, causing vasoconstriction and increasing systemic vascular resistance, which elevates arterial pressure. It may also provide modest beta‑1 stimulation, supporting cardiac output and helping restore circulatory stability.

The dosage is individualized; a qualified prescriber determines the infusion rate and concentration based on the patient’s hemodynamic status, target blood pressure, and clinical response. No fixed regimen is provided here.

Safety data are limited; the drug is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus, and breastfeeding decisions should be made with a healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

The primary alternative is norepinephrine produced by other manufacturers; clinical efficacy is comparable as both are alpha‑adrenergic agonists. Differences may lie in formulation, concentration, packaging, and supplier services such as GMP compliance and global logistics.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original container until use and discard any solution that appears discolored or particulate.

Noradrenalin is given intravenously, typically as a continuous infusion. The solution is added to a compatible IV fluid bag or administered via a syringe pump, with the rate adjusted to achieve the desired blood pressure target under continuous monitoring.

Serious adverse events include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, and peripheral tissue necrosis at the infusion site. Prompt recognition and immediate intervention are essential to mitigate these complications.

Patients with uncontrolled hypertension, known hypersensitivity to noradrenaline or its excipients, and those in whom a rapid increase in vascular tone could be harmful (e.g., severe coronary artery disease) should avoid its use unless a clinician determines that benefits outweigh risks.